BIO-THERA Biopharmaceutical Co., Ltd (SSE: 688177), a global science-based and innovative biopharmaceutical company based in Guangzhou, China, hereinafter referred to as "BIO-THERA" or the "Company", today announced that it has signed license and commercialization agreements with SteinCares for two investigational biosimilars. The Company today announced that it has entered into a license and commercialization agreement with SteinCares for two investigational biosimilars. Under the terms of the agreements, SteinCares will have exclusive distribution and marketing rights for the two biosimilars in Brazil and the rest of Latin America.

Under the terms of the agreements, BIO-THERA will be responsible for the development, manufacturing, commercial supply and filing of marketing applications with the U.S. FDA and the European EMA for the two biosimilars, and SteinCares will be responsible for the filing of marketing applications for the two biosimilars in Brazil and the rest of Latin America, and for their commercialization. SteinCares is familiar with the healthcare system in Latin America and has an established commercial network and marketing capabilities to develop the best possible marketing strategy and maximize the accessibility of both drugs in the region.

Mitchell Waserstein, CEO of SteinCares, said, "Partnering with BIO-THERA means that we are taking a step forward in providing better healthcare to patients in Latin America. We have already launched seven products in this market and this partnership will strengthen our position as a leader in the biosimilar space and make us the partner of choice for global biotechs and global pharmaceutical companies entering the Latin American market. We will adhere to the highest ethical standards and are committed to helping patients access safe, innovative and affordable treatment options."

Dr. Shengfeng Li, Founder and Managing Director of BIO-THERA, said, "By partnering with SteinCares, BIO-THERA can bring high-quality biologics to the Latin American market and provide a new treatment option for patients in need."

https://mp.weixin.qq.com/s?__biz=MzIzNTc3NTM5NA==&mid=2247485230&idx=1&sn=018c4682ac91aaf4d819e3a91a460490&chksm=e8e0b3e3df973af529d379956fe4357d57ffe697e081d37f3c5e36b779dbd4098ae57d2f004d&mpshare=1&scene=1&srcid=0319LX1NKJy6iXEDQ1w2zJjj&sharer_shareinfo=f87f7e0c6c19b0157e66f9f3ffffef8b&sharer_shareinfo_first=f87f7e0c6c19b0157e66f9f3ffffef8b#rd